Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986141 for Prevention of Recurrent Brain Infarction After Acute Ischemic Stroke or TIA
jRCT2080223389Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bms-986141 in ischemic stroke, transient ischaemic attack (TIA) and brain infarction (4 arms), sponsored by Bristol Myers Squibb.
02
Drugs
bms-986141
03
Conditions
ischemic stroketransient ischaemic attack (TIA)brain infarction
Beyond the preview
Go deeper on jRCT2080223389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223389.